Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-01-11
2005-01-11
Wehbe, Anne M. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C424S093200, C424S093210, C435S320100, C435S325000, C435S455000, C536S023100
Reexamination Certificate
active
06841540
ABSTRACT:
The present invention provides a CD40-targeted gene delivery system and a CD40-targeted recombinant adenoviral vector for genetic manipulation of dendritic cells and B cells. Also provided are methods of using this enhanced gene delivery to immune system cells and therefore, enhancing dendritic cell-based immunotherapy.
REFERENCES:
patent: 5543328 (1996-08-01), McClelland et al.
patent: 5871727 (1999-02-01), Curiel
patent: 6284742 (2001-09-01), Curiel et al.
Krul et al. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant salmonella strains Jun. 25, 1996 43. 44-48.*
Radoja et al. Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing pp. 465-479.*
Levine et al. Towards gene therapy of diabetes mellitus pp 165-171 Apr. 1999 vol. 5.*
Thomas J. Wickham et al., Journal of Virology, “Targeted Adenovirus-Mediated Gene Delivery to T Cells via CD3,” Oct. 1997, vol. 71, No. 10 p. 7663-7669.*
Hidde J. Haisma et al., Cancer Gene Therapy. “Targeting of adenoviral vectors through a bispecific single-chain antibody,” Jun. 2000, vol. 6, pp. 901-904.*
Robert B. Mendoza et al., Journal of Immunology, “Cutting Edge:Immunostimulatory Effects of a Plasmid Expressing CD40 Ligand (CD154) on Gene Immunization,” Dec. 1997. 159:5777-5781.*
Marielle Christ et al., Immunology Letters “Gene therapy with recombinant adenovirus vectors evaluation of the host immune response”, Jun. 1997 57:19-25.
Curiel David T.
Tillman Bryan Walter
Frommer Lawrence & Haug
Kowalski Thomas J.
Li Q. Janice
The UAB Research Foundation
Wehbe Anne M.
LandOfFree
Immunomodulation by genetic modification of dendritic cells... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunomodulation by genetic modification of dendritic cells..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulation by genetic modification of dendritic cells... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3398539